Generation of a shelf-stable, broadly-reactive influenza vaccine formulated with TLR4, TLR7/8, or TLR9 stimulating adjuvants.

Vaccine distribution to undeveloped regions of the world is often hindered by the lack of efficient cold-chain networks. In this study, the thin-film freezing (TFF) process was used to freeze-dry next generation influenza vaccines for shelf-stable storage. Influenza H1 and H3 hemagglutinin proteins based upon the computationally-optimized broadly-reactive antigen (COBRA) methodology were mixed with one of three toll-like receptor (TLR) agonists, CpG1826 (TLR9 agonist), INI-2002 (TLR4 agonist), or INI-4001 (TLR7/8 agonist). Following the TFF process, these vaccines were reconstituted phosphate buffered saline (PBS) and delivered intranasally to ferrets. Vaccines containing the TLR4 or TLR7/8 adjuvants had broader HAI activity against the panel of H1N1 and H3N2 influenza viruses than ferrets vaccinated with COBRA HA mixed with the TLR9 adjuvant. However, all vaccinated ferrets from these groups were protected against an H1N1 influenza virus challenge, irrespective of the adjuvant. Overall, the constituted vaccines used following the TFF process were effective at eliciting protective immune responses following intranasal administration to ferrets.

Duke Scholars

Author Dale Jay Christensen Medicine, Hematology